Madrigal Pharmaceuticals, Inc. (MDGL)
$
269.93
-0.94 (-0.35%)
Key metrics
Financial statements
Free cash flow per share
-18.1705
Market cap
6.5 Billion
Price to sales ratio
20.6123
Debt to equity
0.1685
Current ratio
5.9077
Income quality
1.0095
Average inventory
44.7 Million
ROE
-0.5054
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutic candidates aimed at cardiovascular, metabolic, and liver diseases. The company's lead product candidate, resmetirom, is a liver-directed selective thyroid hormone receptor-ß agonist currently in Phase III clinical trials targeting non-alcoholic steatohepatitis. In its recent financial report, the company reported a net loss of -$465,892,000.00 indicating challenges in its operations. However, it also reported an income before tax of -$465,892,000.00 showcasing its pre-tax profitability. The depreciation and amortization expenses were reported at $1,096,000.00 reflecting the wear and tear of its assets. The EBITDA ratio is -$2.50 highlighting the company's operational efficiency, while the gross profit stands at $173,900,000.00 illustrating the company's profitability from core operations. Alongside resmetirom, Madrigal is also developing MGL-3745 as a backup compound. The company maintains a research, development, and commercialization partnership with Hoffmann-La Roche and is headquartered in West Conshohocken, Pennsylvania. In terms of market presence, the stock is priced at $269.93 positioning it in the higher-end market, while the low average trading volume of $357,761.00 indicates lower market activity. With a mid-range market capitalization of $5,993,336,769.00 the company is a steady performer within the biopharmaceutical sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth within the Healthcare sector. This strategic positioning reflects Madrigal Pharmaceuticals' commitment to advancing its product candidates and enhancing shareholder value amidst the challenges it faces in the dynamic biopharmaceutical landscape.
Is Madrigal Pharmaceuticals, Inc. (MDGL) a good investment?
Investing in Madrigal Pharmaceuticals, Inc. (MDGL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Madrigal Pharmaceuticals, Inc. (MDGL)'s stock forecast?
Analysts predict Madrigal Pharmaceuticals, Inc. stock to fluctuate between $200.63 (low) and $377.46 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Madrigal Pharmaceuticals, Inc.'s market capitalization?
As of 2025-05-29, Madrigal Pharmaceuticals, Inc.'s market cap is $5,993,336,769, based on 22,203,300 outstanding shares.
How does Madrigal Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Madrigal Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Madrigal Pharmaceuticals, Inc. (MDGL) stock?
To buy Madrigal Pharmaceuticals, Inc. (MDGL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for MDGL. Place an order (Market, Limit, etc.).
What is the best time to invest in Madrigal Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Madrigal Pharmaceuticals, Inc. stock ever split?
Madrigal Pharmaceuticals, Inc.'s last stock split was 1:35 on 2016-07-25.
How did Madrigal Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $180,133,000 | EPS: -$21.90 | Growth: 9.55%.
Where can I find Madrigal Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.madrigalpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Madrigal Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Madrigal Pharmaceuticals, Inc. stock?
All-time high: $377.46 (2025-02-26) | All-time low: $52.33 (2022-01-28).
What are the key trends affecting Madrigal Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Madrigal Pharmaceuticals' Rezdiffra for NASH achieved $137.3M in Q1 '25 sales, surpassing analyst estimates and indicating strong growth, but the stock hasn't rallied. Near-term catalysts include potential approval of Rezdiffra in Europe, Q2 '25 earnings and business development, with MDGL indicating they are keen to add to their pipeline. Results from the MAESTRO-NASH OUTCOMES trial are not expected until 2027, but recent data from MAESTRO-NAFLD-1 provide some hint of the potential efficacy of Rezdiffra in some patients with cirrhosis.
globenewswire.com
CONSHOHOCKEN, Pa., May 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced positive two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra. Patients (n=122) in the study achieved significant improvements from baseline in liver stiffness, liver fat, fibrosis biomarkers, liver volume and risk scores for clinically significant portal hypertension (CSPH).
zacks.com
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
globenewswire.com
CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its first-quarter 2025 financial results on Thursday, May 1, 2025, prior to the open of the U.S. financial markets.
zacks.com
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
zacks.com
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
benzinga.com
On Wednesday, Madrigal Pharmaceuticals, Inc. MDGL reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom).
seekingalpha.com
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash position improved to $931m, and Rezdiffra's market potential remains significant with no current competitors. Positive study data and upcoming European approval could further boost Rezdiffra's market presence, making Madrigal a prime M&A target.
fool.com
Shares of Madrigal Pharmaceuticals (MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday.
zacks.com
Madrigal (MDGL) came out with a quarterly loss of $2.71 per share versus the Zacks Consensus Estimate of a loss of $4.12. This compares to loss of $5.68 per share a year ago.
See all news
